Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Entasis Therapeutics Holdings

Nasdaq:ETTX
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ETTX
Nasdaq
$37M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Entasis Therapeutics Holdings has significant price volatility in the past 3 months.
ETTX Share Price and Events
7 Day Returns
1.5%
NasdaqGM:ETTX
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-59.3%
NasdaqGM:ETTX
0%
US Biotechs
-11.5%
US Market
ETTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Entasis Therapeutics Holdings (ETTX) 1.5% -46.7% -46.2% -59.3% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • ETTX underperformed the Biotechs industry which returned 0% over the past year.
  • ETTX underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

ETTX Value

 Is Entasis Therapeutics Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Entasis Therapeutics Holdings. This is due to cash flow or dividend data being unavailable. The share price is $2.75.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Entasis Therapeutics Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Entasis Therapeutics Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ETTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.33
NasdaqGM:ETTX Share Price ** NasdaqGM (2020-03-27) in USD $2.75
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Entasis Therapeutics Holdings.

NasdaqGM:ETTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ETTX Share Price ÷ EPS (both in USD)

= 2.75 ÷ -3.33

-0.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Entasis Therapeutics Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Entasis Therapeutics Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Entasis Therapeutics Holdings's expected growth come at a high price?
Raw Data
NasdaqGM:ETTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
12.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Entasis Therapeutics Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Entasis Therapeutics Holdings's assets?
Raw Data
NasdaqGM:ETTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.17
NasdaqGM:ETTX Share Price * NasdaqGM (2020-03-27) in USD $2.75
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:ETTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ETTX Share Price ÷ Book Value per Share (both in USD)

= 2.75 ÷ 3.17

0.87x

* Primary Listing of Entasis Therapeutics Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Entasis Therapeutics Holdings is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Entasis Therapeutics Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Entasis Therapeutics Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ETTX Future Performance

 How is Entasis Therapeutics Holdings expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Entasis Therapeutics Holdings expected to grow at an attractive rate?
  • Unable to compare Entasis Therapeutics Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Entasis Therapeutics Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Entasis Therapeutics Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ETTX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ETTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 12.9%
NasdaqGM:ETTX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 53.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ETTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ETTX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 95 -3 3
2023-12-31 45 -42 3
2022-12-31 16 -81 -67 4
2021-12-31 12 -53 -62 4
2020-12-31 1 -53 -56 4
2020-03-28
NasdaqGM:ETTX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -45 -44
2019-09-30 7 -45 -38
2019-06-30 0 -43 -52
2019-03-31 5 -33 -44
2018-12-31 5 -36 -42
2018-09-30 5 -33 -43
2018-06-30 5 -33 -34
2018-03-31 -34 -35
2017-12-31 -27 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Entasis Therapeutics Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Entasis Therapeutics Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ETTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Entasis Therapeutics Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETTX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.11 0.16 -0.43 3.00
2023-12-31 -1.57 -0.65 -2.35 3.00
2022-12-31 -2.17 -1.26 -3.77 4.00
2021-12-31 -2.19 -1.62 -3.46 4.00
2020-12-31 -3.62 -2.71 -4.20 4.00
2020-03-28
NasdaqGM:ETTX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.33
2019-09-30 -2.90
2019-06-30 -5.21
2019-03-31 -6.62
2018-12-31 -12.31
2018-09-30 -190.86
2018-06-30
2018-03-31 -133.95
2017-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Entasis Therapeutics Holdings will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Entasis Therapeutics Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Entasis Therapeutics Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ETTX Past Performance

  How has Entasis Therapeutics Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Entasis Therapeutics Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Entasis Therapeutics Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Entasis Therapeutics Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Entasis Therapeutics Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Entasis Therapeutics Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Entasis Therapeutics Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETTX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7.00 -43.85 13.77 40.17
2019-09-30 7.00 -37.89 12.15 36.22
2019-06-30 0.00 -52.02 10.70 36.70
2019-03-31 5.00 -44.37 9.83 35.50
2018-12-31 5.00 -42.09 10.16 33.05
2018-09-30 5.00 -43.19 9.99 33.87
2018-06-30 5.00 -33.90 9.26 32.95
2018-03-31 -35.11 7.91 29.59
2017-12-31 -29.92 5.60 25.75
2016-12-31 -19.10 3.33 15.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Entasis Therapeutics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Entasis Therapeutics Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Entasis Therapeutics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Entasis Therapeutics Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Entasis Therapeutics Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ETTX Health

 How is Entasis Therapeutics Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Entasis Therapeutics Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Entasis Therapeutics Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Entasis Therapeutics Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Entasis Therapeutics Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Entasis Therapeutics Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Entasis Therapeutics Holdings Company Filings, last reported 2 months ago.

NasdaqGM:ETTX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 42.16 0.00 41.00
2019-09-30 54.89 0.00 48.81
2019-06-30 57.84 0.00 59.47
2019-03-31 70.57 0.00 74.56
2018-12-31 82.88 0.00 85.09
2018-09-30 90.48 0.00 94.02
2018-06-30 33.00 0.00 33.64
2018-03-31 38.41 0.00 40.12
2017-12-31 48.92 0.00 55.10
2016-12-31 22.07 0.00 26.26
  • Entasis Therapeutics Holdings has no debt.
  • Entasis Therapeutics Holdings has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Entasis Therapeutics Holdings has less than a year of cash runway based on current free cash flow.
  • Entasis Therapeutics Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.4% each year.
X
Financial health checks
We assess Entasis Therapeutics Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Entasis Therapeutics Holdings has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ETTX Dividends

 What is Entasis Therapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Entasis Therapeutics Holdings dividends. Estimated to be 0% next year.
If you bought $2,000 of Entasis Therapeutics Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Entasis Therapeutics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Entasis Therapeutics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ETTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ETTX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Entasis Therapeutics Holdings has not reported any payouts.
  • Unable to verify if Entasis Therapeutics Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Entasis Therapeutics Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Entasis Therapeutics Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Entasis Therapeutics Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Entasis Therapeutics Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Entasis Therapeutics Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Entasis Therapeutics Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ETTX Management

 What is the CEO of Entasis Therapeutics Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Manos Perros
COMPENSATION $2,094,815
AGE 51
TENURE AS CEO 4.8 years
CEO Bio

Dr. Manoussos Perros, Ph.D., also known as Manos, serves as the Chief Executive Officer, President & Director at Entasis Therapeutics Inc. Dr. Perros has been President, Chief Executive Officer & Director at Entasis Therapeutics Limited and Entasis Therapeutics Holdings Inc. since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer's Award in 2010.

CEO Compensation
  • Manos's compensation has increased whilst company is loss making.
  • Manos's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Entasis Therapeutics Holdings management team in years:

1.9
Average Tenure
53
Average Age
  • The average tenure for the Entasis Therapeutics Holdings management team is less than 2 years, this suggests a new team.
Management Team

Manos Perros

TITLE
President
COMPENSATION
$2M
AGE
51
TENURE
4.8 yrs

Ruben Tommasi

TITLE
Chief Scientific Officer
COMPENSATION
$961K
AGE
53
TENURE
4.8 yrs

Mike Gutch

TITLE
CFO, Chief Business Officer & Secretary
COMPENSATION
$659K
AGE
53
TENURE
2.9 yrs

Betzy Keiley

TITLE
General Counsel
AGE
53
TENURE
0.9 yrs

Andy Dawson

TITLE
Head of Human Resources
TENURE
0.8 yrs

John Mueller

TITLE
Chief Development Officer
AGE
59
TENURE
4.8 yrs

Eric Kimble

TITLE
Chief Commercial Officer
TENURE
0.9 yrs

David Altarac

TITLE
Chief Medical Officer
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Entasis Therapeutics Holdings board of directors in years:

2.6
Average Tenure
56
Average Age
  • The average tenure for the Entasis Therapeutics Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Meek

TITLE
Chairman of the Board
AGE
56
TENURE
0.8 yrs

Manos Perros

TITLE
President
COMPENSATION
$2M
AGE
51
TENURE
4.8 yrs

Nick Galakatos

TITLE
Independent Director
COMPENSATION
$17K
AGE
61
TENURE
4 yrs

Dave Hastings

TITLE
Independent Director
COMPENSATION
$63K
AGE
58
TENURE
1.9 yrs

Greg Norden

TITLE
Independent Director
COMPENSATION
$32K
AGE
61
TENURE
3.4 yrs

Heather Behanna

TITLE
Independent Director
COMPENSATION
$12K
AGE
44
TENURE
2.6 yrs

Heather Preston

TITLE
Independent Director
COMPENSATION
$10K
AGE
53
TENURE
2.6 yrs

Paul Ambrose

TITLE
Member of Scientific & Clinical Board

Mark Noe

TITLE
Member of Scientific & Clinical Board

Karen Bush

TITLE
Member of Scientific & Clinical Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Mar 20 Sell Frazier Healthcare Partners Company 19. Mar 20 19. Mar 20 -250,000 $3.00 $-750,875
13. Jan 20 Sell Frazier Healthcare Partners Company 09. Jan 20 09. Jan 20 -50,000 $5.00 $-250,010
X
Management checks
We assess Entasis Therapeutics Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Entasis Therapeutics Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ETTX News

Simply Wall St News

Do Directors Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Shares?

A look at the shareholders of Entasis Therapeutics Holdings Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned.

Simply Wall St -

ETTX Company Info

Description

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.

Details
Name: Entasis Therapeutics Holdings Inc.
ETTX
Exchange: NasdaqGM
Founded: 2018
$36,551,798
13,291,563
Website: http://www.entasistx.com
Address: Entasis Therapeutics Holdings Inc.
35 Gatehouse Drive,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ETTX Common Stock Nasdaq Global Market US USD 26. Sep 2018
Number of employees
Current staff
Staff numbers
48
Entasis Therapeutics Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:41
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/12
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.